Abbott Manufacturing Cuts Will Make Up For Lower Mobic Profits
This article was originally published in The Pink Sheet Daily
Executive Summary
Consolidation and staff reductions in global manufacturing operations are designed to improve gross margins, which have been negatively impacted by sales of lower margin products, such as Mobic and Flomax, which Abbott distributes under a deal with Boehringer. Abbott is cutting 700 manufacturing positions.